17β‑hydroxysteroid dehydrogenase 4 induces liver cancer proliferation‑associated genes via STAT3 activation

Lu,Xin; Kong,Lingyu; Wang,Xi; Liu,Weiran; Ma,Panpan; Jiang,Lingling

doi:10.3892/or.2019.6981

17β‑hydroxysteroid dehydrogenase 4 induces liver cancer proliferation‑associated genes via STAT3 activation

Authors:
- Xin Lu
- Lingyu Kong
- Xi Wang
- Weiran Liu
- Panpan Ma
- Lingling Jiang
View Affiliations

Affiliations: Department of Clinical Laboratory, Tangshan Maternal and Children Hospital, Tangshan, Hebei 063000, P.R. China, College of Integrative Chinese and Western Medicine, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Endocrinology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Chinese Medicine, Tangshan Maternal and Children Hospital, Tangshan, Hebei 063000, P.R. China, Department of Blood Transfusion, Hebei Provincial People's Hospital, Shijiazhuang, Hebei 050017, P.R. China, Department of Biochemistry and Molecular Biology, The Key Laboratory of Neurobiology and Vascular Biology, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
Published online on: January 23, 2019 https://doi.org/10.3892/or.2019.6981
Pages: 2009-2019

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence has implicated that the activation of signal transducer and activator of transcription 3 (STAT3) contributes to the progression of liver cancer by affecting the expression of proliferation‑associated genes. A previous study reported that elevated levels of 17β‑hydroxysteroid dehydrogenase 4 (HSD17B4) are observed in patients with liver cancer. The current study investigated how upregulated HSD17B4 expression promoted the expression of proliferation‑associated genes in rats with liver cancer. HSD17B4 expression in rats with liver cancer was significantly increased compared with the control group as determined by reverse transcription‑quantitative polymerase chain reaction and western blot assays. Immunohistochemical results revealed that STAT3 activation was positively correlated with increased HSD17B4 expression in tumor tissues from patients with liver cancer. Western blot results further suggested that HSD17B4 overexpression increased STAT3 activation via the protein kinase B and the mitogen‑activated protein kinase/extracellular‑signal‑regulated kinase signaling pathways in HepG2 cells. The present study suggested that overexpression may promote HepG2 proliferation by enhancing expression of various downstream targets of STAT3. Targeted inhibition of HSD17B4 may describe a novel approach in the prevention and treatment of liver cancer.

View Figures

View References

1	Shukla SK, Singh G, Shahi KS, Bhuvan and Pant P: Staging, treatment, and future approaches of gallbladder carcinoma. J Gastrointest Cancer. 49:9–15. 2018. View Article : Google Scholar : PubMed/NCBI
2	Cervello M, Augello G, Cusimano A, Emma MR, Balasus D, Azzolina A, McCubrey JA and Montalto G: Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Adv Biol Regul. 65:59–76. 2017. View Article : Google Scholar : PubMed/NCBI
3	Kang KJ and Ahn KS: Anatomical resection of hepatocellular carcinoma: A critical review of the procedure and its benefits on survival. World J Gastroenterol. 23:1139–1146. 2017. View Article : Google Scholar : PubMed/NCBI
4	Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171. 59–76. 2009. View Article : Google Scholar
5	Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 130:1117–1128. 2006. View Article : Google Scholar : PubMed/NCBI
6	Barre B, Avril S and Coqueret O: Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem. 278:2990–2996. 2003. View Article : Google Scholar : PubMed/NCBI
7	Wang HY, Cheng Z and Malbon CC: Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
8	Johnson FM, Saigal B, Tran H and Donato NJ: Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res. 13:4233–4244. 2007. View Article : Google Scholar : PubMed/NCBI
9	Oh SB, Hwang CJ, Song SY, Jung YY, Yun HM, Sok CH, Sung HC, Yi JM, Park DH, Ham YW, et al: Anti-cancer effect of tectochrysin in NSCLC cells through overexpression of death receptor and inactivation of STAT3. Cancer Lett. 353:95–103. 2014. View Article : Google Scholar : PubMed/NCBI
10	Carie AE and Sebti SM: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar : PubMed/NCBI
11	Moeller G and Adamski J: Multifunctionality of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol. 248:47–55. 2006. View Article : Google Scholar : PubMed/NCBI
12	Peltoketo H, Luu-The V, Simard J and Adamski J: 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol. 23:1–11. 1999. View Article : Google Scholar : PubMed/NCBI
13	Markus M, Husen B, Leenders F, Jungblut PW, Hall PF and Adamski J: The organelles containing porcine 17 beta-estradiol dehydrogenase are peroxisomes. Eur J Cell Biol. 68:263–267. 1995.PubMed/NCBI
14	Rasiah KK, Gardiner-Garden M, Padilla EJ, Möller G, Kench JG, Alles MC, Eggleton SA, Stricker PD, Adamski J and Sutherland RL: HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol. 301:89–96. 2009. View Article : Google Scholar : PubMed/NCBI
15	Maleki J, Nourbakhsh M, Shabani M, Korani M, Nourazarian SM, Ostadali DM and Moghadasi MH: 17β-estradiol stimulates generation of reactive species oxygen and nitric oxide in ovarian adenocarcinoma cells (OVCAR 3). Iran J Cancer Prev. 8:e23322015. View Article : Google Scholar : PubMed/NCBI
16	Lu X, Ma P, Shi Y, Yao M, Hou L, Zhang P and Jiang L: NF-κB increased expression of 17beta-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol. Mol Cell Endocrinol. 401:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
17	Kim NH, Heo JD, Kim TB, Rho JR, Yang MH and Jeong EJ: Protective effects of ethyl acetate soluble fraction of Limonium tetragonum on diethylnitrosamine-induced liver fibrosis in rats. Biol Pharm Bull. 39:1022–1028. 2016. View Article : Google Scholar : PubMed/NCBI
18	Bookout AL and Mangelsdorf DJ: Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl Recept Signal. 1:e0122003. View Article : Google Scholar : PubMed/NCBI
19	Fishbein MC, Wang T, Matijasevic M, Hong L and Apple FS: Myocardial tissue troponins T and I. An immunohistochemical study in experimental models of myocardial ischemia. Cardiovasc Pathol. 12:65–71. 2003. View Article : Google Scholar : PubMed/NCBI
20	Song H, Wang R, Wang S and Lin J: A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
21	Jia H, Li Y, Zhao T, Li X, Hu J, Yin D, Guo B, Kopecko DJ, Zhao X, Zhang L, et al: Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunol Immunother. 61:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
22	Fang L, Li G, Liu G, Lee SW and Aaronson SA: p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J. 20:1931–1939. 2001. View Article : Google Scholar : PubMed/NCBI
23	Breitling R, Marijanovic Z, Perovic D and Adamski J: Evolution of 17beta-HSD type 4, a multifunctional protein of beta-oxidation. Mol Cell Endocrinol. 171:205–210. 2001. View Article : Google Scholar : PubMed/NCBI
24	de Launoit Y and Adamski J: Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome. J Mol Endocrinol. 22:227–240. 1999. View Article : Google Scholar : PubMed/NCBI
25	Veldhoven PP, Casteels M, Mannaerts GP and Baes M: Further insights into peroxisomal lipid breakdown via alpha- and beta-oxidation. Biochem Soc Trans. 29:292–298. 2001. View Article : Google Scholar : PubMed/NCBI
26	Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA and Sadar MD: LNCaP Atlas: Gene expression associated with in vivo progression to castrationrecurrent prostate cancer. BMC Med. Genomics. 3:432010.
27	True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, et al: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA. 103:10991–10996. 2006. View Article : Google Scholar : PubMed/NCBI
28	Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM and Isaacs WB: 2005. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate. 63:316–323. 2005. View Article : Google Scholar : PubMed/NCBI
29	Ihle JN: STATs: Signal transducers and activators of transcription. Cell. 84:331–334. 1996. View Article : Google Scholar : PubMed/NCBI
30	Costantino L and Barlocco D: STAT 3 as a target for cancer drug discovery. Curr Med Chem. 15:834–843. 2008. View Article : Google Scholar : PubMed/NCBI
31	Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B and Ichikawa H: Targeting signal- transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: Modern target but ancient solution. Ann NY Acad Sci 1091. 151–169. 2006. View Article : Google Scholar
32	Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, et al: Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 1835. 46–60. 2013.
33	Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, et al: Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol. 170:807–821. 2013. View Article : Google Scholar : PubMed/NCBI
34	Schindler C and Darnell JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 64:621–651. 1995. View Article : Google Scholar : PubMed/NCBI
35	Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE and Inghirami G: Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 11:623–629. 2005. View Article : Google Scholar : PubMed/NCBI
36	Schuringa JJ, Jonk LJ, Dokter WH, Vellenga E and Kruijer W: Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J 347 Pt. 1:89–96. 2000. View Article : Google Scholar
37	Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J and Zhou J: Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol. 17:3922–3932. 2011. View Article : Google Scholar : PubMed/NCBI
38	Chiablaem K, Lirdprapamongkol K, Keeratichamroen S, Surarit R and Svasti J: Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition. Anticancer Res. 34:1857–1864. 2014.PubMed/NCBI